Z-VAD-FMK

製品コードS7023

Z-VAD-FMK化学構造

分子量(MW):467.49

Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.

サイズ 価格(税別)  
JPY 19422.00
JPY 78020.00

カスタマーフィードバック(5)

  • (A) LAN5 cells were untreated (top panels) or treated with 50 µM of the caspase inhibitor Z-VAD-FMK (bottom panels). Cells were co-treated with nothing (No Rx), 1 µM GSK-J4, or 1 µM venetoclax for 48 hours and assayed for apoptosis by flow cytometry.

    Science, 2018, 10(441), doi: 10.1126/scitranslmed.aao4680. Z-VAD-FMK purchased from Selleck.

    After treatment with 1.5 g/l matrine in the presence or absence of 10 nM Baf A1 or 20 nM rapamycin or 10 lM z-VAD-FMK (zVAD) for 24 hrs, the cell viability was measured by CCK-8 assay. Results were expressed as mean±S.E.M. representing at least three independent experiments. *P < 0.05, versus matrine alone group.

    J Cell Mol Med, 2017, 21(6):1171-1181. Z-VAD-FMK purchased from Selleck.

  • (A and B) Western blot analysis examining the effect of zVAD-fmk on the icaritin-induced apoptosis. The caspase inhibitor zVAD-fmk could significantly decrease the icaritin-induced cleaved caspase-3 expression. β-Actin protein levels indicate that an equal amount of protein was loaded into each lane.n=3. Mean±SD. bP<0.05, compared to the control group. eP<0.05, compared to the icaritin-treated group.

    Acta Pharmacol Sin 2014 35(4):531-9. Z-VAD-FMK purchased from Selleck.

    Active caspase-3 expression analysis. SW1116 cells were treated with ZBH-1205, CPT-11 and SN38 at 25 μmol/L for 48 h, in the presence or absence of Z-VAD-FMK (50 μmol/L, 1 h ahead of time). *P= 0.0345. Z-VAD-FMK(-) vs. Z-VAD-FMK(+). E: Cell cycle analysis. F: Apoptosis analysis. #P=0.0259. Z-VAD-FMK(-) vs. Z-VAD-FMK(+). ALL experiments were repeated three times.

    Arch Biochem Biophys, 2016, 604:74-85.. Z-VAD-FMK purchased from Selleck.

  • Effect on the RAS of CFZ, z-VAD-fmk, or CFZ + z-VAD-fmk treatments administered 5 or 12 days after C26 inoculation and control groups. Western blot analysis of ATF2 and pATF2. CP, ZP and UP were treated for 5 days; CT, ZT, UT and CC were treated for 12 days. CFZ (CP), z-VAD-fmk (ZP), CFZ + z-VAD-fmk (UP), PBS only (CC), healthy control (HC).

    Med Oncol, 2015, 32(4): 538 . Z-VAD-FMK purchased from Selleck.

製品安全説明書

Caspase阻害剤の選択性比較

生物活性

製品説明 Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.
特性 A key compound for apoptosis studies.
ターゲット
Pan-caspase [1]
(THP.1, Jurkat T-cells)
体外試験

Z-VAD-FMK (10 mM) inhibits apoptosis in THP.1 cells. Z-VAD-FMK (10 μM) inhibits activation of PARP protease activity in control THP.1 cell lysates. Z-VAD-FMK (10 mM) inhibits the processing of CPP32 in intact THP.1 and Jurkat cells. [1] Z-VAD-FMK (50 μM) cotreatment abolishes the apoptotic morphology of camptothecin-treated HL60 cells. Z-VAD-FMK (50 μM) blocks camptothecin-induced DNA fragmentation in HL60 cells. [2] Z-VAD-FMK (50 μM) inhibits cell death following dSMN dsRNA-induced apoptosis in S2 cells. Z-VAD-FMK (50 μM) increases the percentage of transfected cells surviving from 26% to 63% in S2 cells. [3] Z-VAD-FMK (> 100 μM) enhances TNFα-induced neutrophil apoptosis, lower concentrations (1-30 μM) completely blocks TNFα-stimulated apoptosis in human neutrophils. [4] Z-VAD-FMK (10 mM) inhibits apoptosis in anterior stromal keratocytes. Z-VAD-FMK (10 mM) inhibits apoptosis in anterior stromal keratocytes detected with the TUNEL assay. [5]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
GC1a NV;6T4RLSXCxcITvd4l{KEG|c3H5 M4\zZ|Ux|ryP M3zX[FI1cA>? MmKwbY5lcWOjdHXzJIEheHKxdHXjeIl3\SCnZn\lZ5Qh[WejaX7zeEBmfG:yb4Pp[IU> NVfHVoZbOjZzNkmwO|U>
HGL5 NHfw[HNCeG:ydH;zbZMhSXO|YYm= MVy1NO69VQ>? M2rEOFI1cA>? MY\pcoRq[2G2ZYOgZUBxem:2ZXP0bZZmKGWoZnXjeEBi\2GrboP0JIV1d3Cxc3nk[S=> NYiyVo1ROjZzNkmwO|U>
HepG2 NWTtV45XSXCxcITvd4l{KEG|c3H5 MlzYNlDPxE1? MYGxbC=> M3r2e4F1fGWwdXH0[YQhfGinIHHwc5B1d3SrYzDpcoR2[3Srb36gc4YhUUmLLUGwxsA> NYXOWIlOOjZzNkS3PVU>
BEL-7402 M{LIUWFxd3C2b4Ppd{BCe3OjeR?= NUPSbWprOjEQvF2= MW[xbC=> NXHoUWNJ[XS2ZX71ZZRm\CC2aHWgZZBweHSxdHnjJIlv\HWldHnvckBw\iCLSVmtNVDDqA>? M4Tt[|I3OTZ2N{m1
CEF MlvET4lv[XOnIFHzd4F6 Ml2wNEw{Oyx4NzyxNFDPxE1? MWqxOY1qdg>? M3;odYRwf25vcnXneYxifGW|IGDSJIVvgnmvZTDhZ5Rqfmm2eTD0c{A1OO,:hTDheEAyODEQvF2= NVrL[FBEOjZzMEKzN|k>
SP2/0 NH7ETZNCeG:ydH;zbZMhSXO|YYm= Mmn5NVAx|ryP MoraNYg> NVPreFJnTE2VTx?= NHTKcnFjdG:la4OgeIhmKGGyb4D0c5NqeyCxZjDTVFIwOCClZXzsdy=> M3ThSlI3ODd2N{Oy
HUVEC-2c NX7GPWJGSXCxcITvd4l{KEG|c3H5 NIHrd2Y2OM7:TR?= MYm2bC=> Mliy[IVkemWjc3XkJJRp\SCxeD3MSGwucW6mdXPl[EBifXSxcHjh[5k> Mmj0NlYxOjF5Mkm=
U1 NVfUNlJmSXCxcITvd4l{KEG|c3H5 NXHWWI5TOC1zMEFOwG0> M4\uU|Jp M3HUO5Jm\HWlZYOg[JJ2\y2rbnT1Z4VlKGGyb4D0c5NqeyCjbnSgd5Vje2WzdXXueEBJUVZvMTDy[ZBtcWOjdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NHy5N5AzPTl6MEm0Ni=>
ACH-2 MVHBdI9xfG:|aYOgRZN{[Xl? NVPKNVRzOC1{MEFOwG0> NXPlXY1FOmh? NYC1WJJQemWmdXPld{BlenWpLXnu[JVk\WRiYYDvdJRwe2m|IHHu[EB{fWK|ZYH1[Y51KEiLVj2xJJJmeGyrY3H0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NYj0bVZNOjV7OEC5OFI>
U1 MY\LbY5ie2ViQYPzZZk> M1y4blExOM7:TR?= M3j6NVJp MlTIbY5pcWKrdIOgZ4F{eGG|ZT2z MVyyOVk5ODl2Mh?=
A549/V16 M1qxZ2Fxd3C2b4Ppd{BCe3OjeR?= MWC1NO69VQ>? M{PUOVFp NH7SZY5z\XC{ZYPz[ZMhXEdxVF2tbY5lfWOnZDDhdI9xfG:|aYO= M4fKe|I2QTR4MEOz
SGN NE\lW3dCeG:ydH;zbZMhSXO|YYm= NWLmcZVPOjCvTR?= Mm\JOFhp MUnoZZMhdm9iaX7mcJVmdmOnIH;uJGFKTixiY3HsdIFqdiCneIDy[ZN{cW:wIH;yJINmdGxiYYDvdJRwe2m| NV7vOVd5OjV6N{S2N|M>
HCT116  M{fuZ2Fxd3C2b4Ppd{BCe3OjeR?= NH7Mc3I2OM7:TR?= NEHnTWgzcA>? M1PSWYlvcGmkaYTzJJRp\SClZXzsJIRm[XSqIHnu[JVk\WRiYomgSGRXWA>? NGHIPHczPTh4OEixPC=>
DTK-SME M2C1OmFxd3C2b4Ppd{BCe3OjeR?= NVfq[3FOPTEQvF2= MWiybC=> NEjjfFRFVVOR MUTwZZJ1cWGubImgbY5pcWKrdIOgeIhmKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IHL1dIl3[WOjaX7l MUKyOVg1Ozh7Nx?=
HL-60 M3fGRmFxd3C2b4Ppd{BCe3OjeR?= NHXtN3M2OM7:TR?= MYO0PIg> M4TkRZJm\HWlZYOgZ4VtdCCmZXH0bEBk[XW|ZXSgZpkhW0uLLVnJJJRz\WG2bXXueOKh M4fBe|I2QDJ2MESz
U937 MlHkRZBweHSxc3nzJGF{e2G7 MVu1NO69VQ>? MnPyOFhp Mmn1doVlfWOnczDj[YxtKGSnYYToJINifXOnZDDifUBUU0lvSVmgeJJm[XSvZX70xsA> M1mwNVI2QDJ2MESz
A549 M4\0VmFxd3C2b4Ppd{BCe3OjeR?= NVzySW1uOjBizszN MX6yOIg> MnjZdoVlfWOnczDj[YxtKGSnYYToJINifXOnZDDifUBJTkOSIITy[YF1dWWwdB?= NFjVdIozPTd7NEG0PS=>
HeLa NXqwRoV1SXCxcITvd4l{KEG|c3H5 NEnLUFEyOM7:TR?= NGPPNI01QGh? M13j[4Rm[2yrbnXzJJRp\SC{YYTlJI9nKGGyb4D0c5NqeyCmcnHtZZRq[2GubIm= NHi5UIIzPTd5MkW0OS=>
SGC-7901 NWDkdmlGSXCxcITvd4l{KEG|c3H5 NFLvfY8zOMLizszN MlztNYg> NFzWOFdqdmirYnn0d{B1cGViY3XscEBl\WG2aDDpcoR2[2WmIHL5JI95[WyrcHzheIlv MlLBNlU4PjdyN{[=
MCF-7 NEPYfWJCeG:ydH;zbZMhSXO|YYm= MW[xNO69VQ>? NF7uWW4zcA>? MnnZbY5pcWKrdIOgeIhmKGOnbHyg[IVifGhiaX7keYNm\CCkeTCzRi=> NVrR[5RGOjV5MkKxNVQ>
A549 NGTubYFCeG:ydH;zbZMhSXO|YYm= M3[1e|ExKM7:TR?= NXfL[HNNOjSq MkjvSG1UVw>? NHXNT4Nxem:vb4Tld{BJSkNvdILlZZRm\CCDNUS5JINmdGxic4Xyeol3[WxiJjDheJRmdnWjdHXzJJRp\SClbHXheoVlKFCDUmCg[ZhxemW|c3nvci=> NVXFTmVQOjV4OEO1Olg>
U87 M{PLT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYi1NO69VQ>? NFTCVFkycA>? MWLy[YNwfmW{czDj[YxtKGe{b4f0bEBnem:vIGTNXkB1emWjdH3lcpQ> MWiyOVY5OTZ4OB?=
Neocortical Neuron Mn;PUoV2em:2b4jpZ4l1gSCDc4PhfS=> M3y4e|ExOM7:TR?= MXmxbC=> M4TRfoFvfGGpb37pfoV{KEixaXHtbYRmKEFvSX7keYNm\CCQZYXyc5RwgGmlaYT5 NFLn[3gzPTZ5NUCwNS=>
Primary human placental cytotrophoblasts MlHwRZBweHSxc3nzJGF{e2G7 NIXnPHE{OM7:TR?= NVfJ[oNYOjSq NX63XGpuTE2VTx?= NUXFcZUyemW4ZYLz[ZMhfGinIHnubIljcXSrb36gc4YhOTIQsj3IV2QzKGK7IITybYNtd3OjbtMg NGj6[FMzPTZ2MkW5Ni=>
MM MVfBdI9xfG:|aYOgRZN{[Xl? M121UVUx|ryP M1H5XVIxdWmw MVLwZZJ1dHliaX7obYJqfHNiU1jLMYlv\HWlZXSgJINmdGxiZHXheIg> NXi3boFrOjV3M{CwPVg>
DLD1 NHfFZlNCeG:ydH;zbZMhSXO|YYm= MmjtNlDDqM7:TR?= NYHPfZc3OWh? M2HY[5BienSueTDy[ZZmenOnczDj[YxtKGGyb4D0c5NqeyClYYXz[YQh[nliV2PQNS=> MVeyOVUzPDJ2Nh?=
MDA-MB-231 NYPweVVSS3m2b4TvfIlkcXS7IFHzd4F6 M{nTfFEx|ryP MYGxbC=> NIKwNZpifWevZX70d{Bk\WyuIHTlZZRpKGGodHXyJGNJXUFidILlZZRu\W62 NHTFUWMzPTV{MUWwNS=>
MKN28 NIi3Om1CeG:ydH;zbZMhSXO|YYm= NXziTYx1OTEQvF2= MmD1N|BucW5? M1WzfGROW09? NWK0dYl{cW6qaXLpeJMhXE6ILd8xJJBtfXNiQ1jYMYlv\HWlZXSgZZBweHSxc3nz M4H1PFI2PTF|OU[w
HL-60 NX7XR3hyS3m2b4TvfIlkcXS7IFHzd4F6 NX30TJk3OTByzszN NXHSb5FpOWh? M4[wdGROW09? MYRCpIlueHKxdnXzJJZq[WKrbHn0fUBw\iCWQ17Bd{11emWjdHXkJINmdGy| NHSxOm8zPTVyMkmzNi=>
AGS NVTLSmlOSXCxcITvd4l{KEG|c3H5 MUWxNO69VQ>? M1rVZ|Fp NYm3UoM2eHKndnXueJMh[3W{Y4XtbY4ucW6mdXPl[EBkdGWjdnHn[UBw\iClYYPwZZNmNTNuID24MEBidmRiLUmgdJJwfGWrboO= MnPxNlU1QTJ{MUS=
A549  MkTXRZBweHSxc3nzJGF{e2G7 MYSxNO69VQ>? M3fpRlI1cA>? NEXvbHhjdG:la4OgSG1CWy2rbnT1Z4VlKGOuZXH2ZYdmKG:oIHPhd5Bie2VvMzDhcoQhWEGUUDDhcoQh[XCxcITveIlkKGOnbHyg[IVifGh? MnzhNlU1OzR7OEm=
INS-1 NVXQZ3RCSXCxcITvd4l{KEG|c3H5 MWi1NO69VQ>? NGe4OFg3cA>? Mn7VSG1UVw>? NVPMNG5Y\GWlcnXhd4V{KHSqZTDwdo9xd3K2aX;uJI9nKGWjcnz5JIFxd3C2b4TpZ{Bk\Wyuc9Mg M{TYPFI2PDNyOEm3
Primary hepatocytes  M2XzPWFxd3C2b4Ppd{BCe3OjeR?= MXW1NO69VQ>? NV73XJRtOTiq NWfGOXl6cW6qaXLpeJMh[XCxcITvd4l{KG:oIHjldIF1d2O7dHXzJIlv\HWlZXSgZpkhSWO2IFSgZY5lKFSQRj5OtS=> MlLUNlU1ODd3M{i=
L929-A  NWXDRY86S3m2b4TvfIlkcXS7IFHzd4F6 MViyNOKh|ryP MUKyOIg> M{TCeolvcGmkaYTzJHRPTs7zLXnu[JVk\WRiY3XscEBl\WG2aB?= M1;hXVI2Ozl6NUSw
L929-N MYnDfZRwfG:6aXPpeJkhSXO|YYm= NF3jZmwzOMLizszN MWCyOIg> Mlri[Y5p[W6lZYOg[IVifGhidnnhJIF2fG:lcnnu[UBVVkcQsTDwdo9lfWO2aX;u M4naVlI2Ozl6NUSw
Cytotoxicity Assay MmrVR4VtdCCYaXHibYxqfHliQYPzZZk> NGj1NJMzOM7:TR?= NVXFRmxqPDiq M17XWJBz\X[nboSgUWhOTC2rbnT1Z4VlKGOnbHyg[IVifGh? NHmxSnQzPTN7MkGxOi=>
COS7 M3S5d2tqdmG|ZTDBd5NigQ>? MnO4NVDPxE1? M3vFOlI1cA>? MXzpcoNz\WG|ZYOgZ4F{eGG|ZTCzM|ch[WO2aY\peIlmew>? NFX6O4QzPTN6NECyOS=>
COS7 MV3BdI9xfG:|aYOgRZN{[Xl? Ml;DNVDPxE1? MkTQOFhp MknsdIFzfGmjbHz5JJBz\X[nboTl[EBHSzFyMT3pcoR2[2WmIHPlcIwh\GWjdHi= NIL6T4kzPTN6NECyOS=>
A375 NX7GOHRNSXCxcITvd4l{KEG|c3H5 NWDybVFCOzEQvF2= NFHYfI8zcA>? NVHYVHJZeHKndnXueJMhfGinIHTyeYcucW6mdXPl[EBRSVKSIHPs[YF3[Wen MmrlNlU{PzZzMUW=
A549 M{izR2Fxd3C2b4Ppd{BCe3OjeR?= NUnONpQ3PTEQvF2= M{S4dFI1cA>? M3\oRpJmfmW{c3XzJJJq[m:|b33lJIJqd2enbnXzbZMh[W6mIHHwc5B1d3OrczDjZZV{\WRiYomgJGNpcWqxbnfkZY4> M3TCcFI2OzR7N{ix
A549 NFjrZpNCeG:ydH;zbZMhSXO|YYm= NX;ZZ3lsOi53LUK1{txO NH7lO|UycA>? Mn[1[IVkemWjc3XzJJRp\SCyb4D1cIF1cW:wIH;mJIFxd3C2b4TpZ{Bk\WyuczDk[ZBmdmRib36gZ49v[2WwdILheIlwdnN? NF3aOXgzPTN2MkSyOy=>
 NBL-W-S  NX\Fbm1ISXCxcITvd4l{KEG|c3H5 MmK5OVDPxE1? NWrIRo1uOWh? NGjmeZVnfWyueTDy[ZNkfWW|IHPlcIwhfmmjYnnsbZR6KGGodHXyJGdCVlRvNkGgeJJm[XSvZX70 MXSyOVMzOzJ{Mh?=
Caki-1  NGnt[HBCeG:ydH;zbZMhSXO|YYm= Mlj4OFDPxE1? M3XzUFQ5cA>? MYTy[YR2[2W|IITo[UBvfW2kZYKgc4YhSW6wZYjpckBXNXCxc3n0bZZmKGOnbHzz M{HLXFI2Ojd7MUmx
769-P MmXBRZBweHSxc3nzJGF{e2G7 MYK0NO69VQ>? NXXm[lE2PDiq MXHy[YR2[2W|IITo[UBvfW2kZYKgc4YhSW6wZYjpckBXNXCxc3n0bZZmKGOnbHzz M3nnTFI2Ojd7MUmx
H9c2 M4O1[GFxd3C2b4Ppd{BCe3OjeR?= MYe1NO69VQ>? M4nHXFFp NXTMeopjcW6qaXLpeJMhTE:[LXnu[JVk\WRiY3HzdIF{\SB|IHHjeIl3[XSrb36gZpV1KG6xdDD0bIUhdG:|czDv[kBk\Wyucx?= MoL5NlUzQDN6MUm=
K562 MVPBdI9xfG:|aYOgRZN{[Xl? MkPhOVDPxE1? M2GyOFRp M3\NPIlvcGmkaYTzJGpi[y2DLXnu[JVk\WRiY3XscEBieG:ydH;zbZM> MWOyOVI1OTZzOR?=
L929 MlTCRZBweHSxc3nzJGF{e2G7 M3m5TVEx|ryP MXW2bC=> NULVWVlTcW6mdXPld{Bv\WO{b4D0c5NqeyC5aYToJHRPTg>? MojVNlUyQTV4NkC=
A549 NIfzWnZCeG:ydH;zbZMhSXO|YYm= Mln2NVDPxE1? NXW0Z3o4O2h? MYXy[YR2[2W|IHPlcIwh[XCxcITvd4l{KGOjdYPl[EBjgSCSUWG= MV:yOVE3OTZ7OR?=
MCF-7 MV3BdI9xfG:|aYOgRZN{[Xl? NU\5O2VmOjEQvF2= NFvwb4kzcA>? NYK1SlRp\GWlcnXhd4V{KEuGUj3zbXJPSS2rbnT1Z4VlKGGyb4D0c5Nqew>? NU\mNHdnOjVzOEKyOFA>
OS NFznTYhCeG:ydH;zbZMhSXO|YYm= MYGyNE81OM7:TR?= NGXNVXU4Omh? M3THTolvcGmkaYTzJG9UKGOnbHygeoli[mmuaYT5JJJm\HWldHnvckBjgSCFNjDj[ZJidWmmZR?= NVvBS5VKOjVzNUKzPVk>
HUVECs NVXKUXh6SXCxcITvd4l{KEG|c3H5 M17qRlEx|ryP MUOybC=> MVhCpIlvcGmkaYTzJIFxd3C2b4Ppd{BidmRiZnHjbYxqfGG2ZYOgZZV1d3CqYXf5JIlvKESHTm[yMYlv\mWldHXkJGhWXkWFcx?= MWWyOVE{QDdyMx?=
EA.hy926 NHTXSohCeG:ydH;zbZMhSXO|YYm= MojlNVDPxE1? Mk\VNog> NH;YOnLDqGmwaHnibZR{KGGyb4D0c5NqeyCjbnSg[oFkcWyrdHH0[ZMh[XW2b4DoZYd6KGmwIFTFUnYzNWmwZnXjeIVlKEWDLnj5PVI3 Mm\NNlUyOzh5MEO=
Ebs M{XDeGFxd3C2b4Ppd{BCe3OjeR?= M4r2WVExNTFyMN88US=> M3roWFI1cA>? Ml3LxsBOVVSVIHflcoVz[XSrb36gdoF1\SCmZXPy[YF{\WRiYYOgeIhmKGOxbnPlcpRz[XSrb36gc4Yhgi2YQVSu[o1sKGmwY4LlZZNm\A>? NHfLXnAzPTF|NEixOy=>
Jurkat MojORZBweHSxc3nzJGF{e2G7 NF;EW4EzOM7:TR?= M2r0NlI1cA>? NVHKXY9MTE2VTx?= MUfwZZJ1cWGubImgbY5pcWKrdDDj[YxtKGSnYYToJI9nKEq3cnvheEBk\WyuczDpcoR2[2WmIHL5JFExODV6LV[0JINwdWKrbnXkJJdqfGhiVmDBxsA> M3GyNFI2OTJyN{Kz
K562 NITMXYlCeG:ydH;zbZMhSXO|YYm= NXTjNph7OC5zLUJOwG0> NFn3PZYycA>? NHPSbpdqdmirYnn0d{BkdGWjdnHn[UBw\iCKU2C5NEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> Mk\aNlUyOTlzOEi=
IMR-32 MX\BdI9xfG:|aYOgRZN{[Xl? NEjkXWw1OMLizszNxsA> NWm1PWI5Omh? M4\VZoRm[3KnYYPlJIlvKGGyb4D0c5Rq[yClZXzsd{Bkd22yYYLl[EB1dyCWLUKgeI95cW5? MXyyOVA5PDd3NR?=
RPMI 8226 NWHNbphKSXCxcITvd4l{KEG|c3H5 MnLkNVAx|ryP M1nRTFFp MkjoZYxud3O2IHPvcZBt\XSnbImgZoxw[2u|IHPlcIwh\GWjdHigZ4F2e2WmIHL5JI5m[3Kxc4TheIlvNTF? MUiyOVA{Pzh3MR?=
U266  NUnO[ZBHSXCxcITvd4l{KEG|c3H5 MVixNFDPxE1? MkPINYg> NEL4fZpx[XK2aXHscJkh[myxY3vzJINmdGxiZHXheIgh[2G3c3XkJIJ6KG6nY4Lvd5RifGmwLUG= NEmx[ZQzPTB|N{i1NS=>
H929  M2e0RWFxd3C2b4Ppd{BCe3OjeR?= NIDoZYEyODEQvF2= NX\velZjOWh? NGfUdGVx[XK2aXHscJkh[myxY3vzJINmdGxiZHXheIgh[2G3c3XkJIJ6KG6nY4Lvd5RifGmwLUG= MXeyOVA{Pzh3MR?=
MM.1S  NHTTbGJCeG:ydH;zbZMhSXO|YYm= NVTCOoJwOTByzszN MUmxbC=> M2\FVYVn\mmlaXXueIx6KHC{ZY\lcpR{KHOxcnHm[Y5q[i2rbnT1Z4VlKGOnbHyg[IVifGhiY3;tZolv\SC5aYToJI5m[3Kxc4TheIlvNTF? NI\Yd2YzPTB|N{i1NS=>
C6 MmjIRZBweHSxc3nzJGF{e2G7 NXflV5NEPTEQvF2= NGHtV|E1QGh? M3z1[pBz\X[nboTzJJRp\SCub4PzJI9nKGOnbHygeoli[mmuaYT5JINifXOnZDDifUBxemWpbnXuc4xwdmV? MVWyOVAyOzR5OR?=
AGS NX;EeFV5SXCxcITvd4l{KEG|c3H5 NH\KeJc2OM7:TR?= NX3Vb3lMOjSq M1zLUIFjd2yrc3jzJO6zNWyjcHHjbI9v\S2rbnT1Z4VlKGOnbHyg[IVifGhiYX7kJIlvcGmkaYTl[EBoem:5dHi= M4XkSlI2ODB7Nkm4
HeLa  NXzsSJl[SXCxcITvd4l{KEG|c3H5 MmDTOFDPxE1? MViyOIg> MYDpcohq[mm2czD0bIUhcW6lcnXhd4VlKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IIPpVm5HOTJz NGXFWGwzPDl{OE[4OS=>
THP-1  NYDCdpZGSXCxcITvd4l{KEG|c3H5 NUnUT3dJOTEQvF2= NHftfJMycA>? M1zSZpJm\HWlZYOgZZBweHSxc3nzJIlv\HWlZXSgZpkhSUyDLWPEWOKh MnTrNlQ6OjN4NUO=
P815  MmfPRZBweHSxc3nzJGF{e2G7 MUixNFAhyrWP NE[z[o4yOmh? MYXEUXNQ M1vSTYlvcGmkaYTzJJZqenW|LXnu[JVk\WRiYYDvdJRwe2m| MV[yOFkzOzJ5Mx?=
HCT116 MkHBRZBweHSxc3nzJGF{e2G7 M1PvWVIx|ryP MVeyOIg> MYnhZpJw\2G2ZYOgc4YhXFFvaX7keYNm\CCjcH;weI9{cQ>? M2DOOVI1QDlyNES5
SW1116  NXTBPXFYSXCxcITvd4l{KEG|c3H5 NX7GZphMOTBiwsXN M{jISVFp NI[5N4lFVVOR MX3y[ZN1emGrboOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDn[YZqfGmwaXKgdIx2eyCmZXPpeIFjcW6n M33C[FI1QDd2Mki2
LOVO M4LiWmFxd3C2b4Ppd{BCe3OjeR?= M4rwOFExKML3TR?= NHLsOpUycA>? M3HNWWROW09? M3fYbpJme3S{YXnud{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JIdm\mm2aX7pZkBxdHW|IHTlZ4l1[WKrbnW= NXvnU5NbOjR6N{SyPFY>
SNU449  NXSxN3RrSXCxcITvd4l{KEG|c3H5 MX6yNO69VQ>? MoX4OFhp MoO3SG1UVw>? M1uwRoRm[3KnYYPld{BucVJvNEWxMYlv\HWlZXSgZZBweHSxdHnj MmHGNlQ5PDF4M{i=
Caco-2 MV7BdI9xfG:|aYOgRZN{[Xl? MX:0NQKBkc7:TR?= M2DYb|Rp NIHBUW5xemW4ZX70d{BUXC15LXnu[JVk\WRiWl:tNUBkcGGwZ3XzJIFv\CCWRWKg[JJweA>? NWTxe2d3OjR6MkKxPFM>
macrophage NHL4[VBE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MlG1NE0zODEQvF2= NF7SVGczPGh? NWrqcGJ[cW6mdXPld{BVVkZvIHHu[EBTcXB|LXTldIVv\GWwdDDu[YNzd3C2b4Ppd{BqdiCvYXPyc5Bp[Wen MV2yOFc6QTV4NR?=
AGS  MoDhRZBweHSxc3nzJGF{e2G7 MkLqNlDPxE1? NHjQSJAyOmh? NULZfVl5TE2VTx?= NIW3PI5z\WS3Y3XzJJRp\SCrbnT1Z5Rqd25ib3[gZZBweHSxc3nzJIlvKHKnc4DvcpNmKHSxIITo[UBGfE:DYzDmdoFkfGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NF7RdngzPDd6OUewNy=>
LCC9  MVTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NYXjW3R5OTByzszN NGj0cI02\A>? MmXQZoxw[2u|IHPlcIwh\GWjdHigbY5lfWOnZDDifUBkd22kaX7heIlwdiCOMUegZY5lKGOqbH;yc5F2cW6n MY[yOFc5PTJ3Nh?=
U937  MVvu[YNzd3C2b4Ppd{BCe3OjeR?= NF\kfI0yOMLizszN NHfE[pA{OMLibXnu MmjpbY5lfWOnczDu[YNzd3C2b4Ppd{Bkd22kaX7lJJdqfGhiVF7G NIfBVGczPDd5M{e1Oi=>
T cell NWT2R5lvS2WubDDwdo9tcW[ncnH0bY9vKGG|c3H5 NUXnWphsOC1zMEFOwG0> MX:3Nog> MnrjTWM2OD15MDFOwG0tKGmwaHnibZR{KGGwdHmtR2Q{NWmwZIXj[YQhXCClZXzsJJBzd2yrZnXyZZRqd25iaX6gVGJOS3N? NGfud3AzPDd4OEewOy=>
HeLa  M1rpTmFxd3C2b4Ppd{BCe3OjeR?= MX61NO69VQ>? NXHTeIFoPzKq NXO0PGdVTE2VTx?= MkHFdJJmfmWwdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkh[2:vcH;1coR{yqBz4pETOS=> M4HpblI1PzV2N{i2
HeLa  M2TMSmFxd3C2b4Ppd{BCe3OjeR?= MX2xNFDPxE1? MnvQNlRp MY\zeZBxemW|c3XzJJJifGVib3[gZ4VtdCCmZXH0bEBqdmS3Y3XkJIJ6KG:4ZYLlfJBz\XO|aX;uJI9nKEd3OWOgc5IhTzdzUjDwNVUx\2y3ZXVCpC=> M4fIdVI1PzJ{NE[4
IEC-6  MkXjRZBweHSxc3nzJGF{e2G7 NYe5N3ZrOTEQvF2= NILlZW0zPGh? MknzdJJmfmWwdIOgWINlSS2rbnT1Z4VlKGOjc4Dhd4UuOyClbHXheoFo\SCjbnSg{tIu[2G2ZX7pckBl\We{YXTheIlwdg>? MojxNlQ4OTF3N{G=
HCT116 Mn7JRZBweHSxc3nzJGF{e2G7 NHrKVWwzOM7:TR?= MWKyOIg> MmDUbY5pcWKrdIOgeIhmKGOnbHygZZBweHSxdHnjJIlv\HWlZXSgZpkhYUyWMkC1 M1XEdVI1PzF|OEGy
L02 NFzpTVRCeG:ydH;zbZMhSXO|YYm= MofhNlDPxE1? NIr2N2cycA>? NUL5NmJKeHKndnXueJMhfGinIHPlcIwh[XCxcITvd4l{KGmwZIXj[YQh[nliTVXIVC=> NFTh[WUzPDdyNkS2NS=>
A375 M{XncGFxd3C2b4Ppd{BCe3OjeR?= MlWyNlDPxE1? NXHYW|dyOjSq M3;ScpJmfmW{c3XzJIRq[2m2cnnuc45mKEJvaX7keYNm\CCjcH;weI9{cXN? NU\BWmY2OjR4OUmxNVE>
HDPC M3XUemFxd3C2b4Ppd{BCe3OjeR?= MYK1NOK2VQ>? MkjwNlRp NVr3dZAzcW6qaXLpeJMhVk9vaX7keYNm\CCjcH;weI9{cXN? MUCyOFY{PDV7Mx?=
A549 M1\hUGFxd3C2b4Ppd{BCe3OjeR?= NYHpRnRMPTEEtV2= NWPyXFJKOmh? M1;u[WROW09? NXH3dnpveHKndnXueJMhfGinIHj5dI9lcXCub3nkJGRPSSClb370[Y51KHCqYYPlJIlv\HWlZXSgZpkh[2WyaHHsc4Npem:vaX6= MlfBNlQ2QDhzM{W=
 BV-2 NVj2c2VCSXCxcITvd4l{KEG|c3H5 M3\UZVIx|ryP MVGybC=> NIfJdFF{fXCycnXzd4V{KFWYLXnu[JVk\WRiY3jyc41ifGmwIHX4eJJ2e2mxbjDhcoQh\GmuYYTpc44hd2ZidHjlJI52[2ynYYKg[Y53\WyxcHW= NWnlOWw1OjR3NUixNVg>
HT-29  MWDBdI9xfG:|aYOgRZN{[Xl? NGXoU5A2OM7:TR?= NX:0[Yx6PDiq M1XUTYJtd2OtczD0bIUh[XCxcITvd4l{KGmwZIXj[YQh[nlia3HlcZBn\XKxbB?= Mnf2NlQ2PDlzN{W=
A549 MUTBdI9xfG:|aYOgRZN{[Xl? MVe1{txO NVe2R|BDOjSq MWHzeZBxemW|c3XzJFZmyqBqQluxNFA1OClvaX7keYNm\CCjcH;weI9{cXQEoB?= M4nBUFI1PTJ7OEex
MIA-PaCa-2 MmPlRZBweHSxc3nzJGF{e2G7 M3Lqe|I1cA>? Ml:3Zoxw[2u|IHPs[YF3[WenIH;mJINie3Cjc3WtN{BqdmS3Y3XkJIJ6KGKxdHigRU01PDN4NUSgZY5lKHCjY3zpeIF5\Wx? M3vGU|I1PTFyOUmy
Caki-1 MVrBdI9xfG:|aYOgRZN{[Xl? MlX1NlDPxE1? NWnnPWJYOWh? M4nNdYlvcGmkaYTzJHNEWC2rbnT1Z4VlKGGyb4D0c5Nqew>? MkTrNlQ2ODR4OEG=
CLL MkfTRZBweHSxc3nzJGF{e2G7 MYKyOe69VQ>? Mmq4NYg> NYDPZ254eGG{dHnhcIx6KGKub3Prd{BOVE5{MkO4MYlv\HWlZXSgZ4VtdCCjcH;weI9{cXN? M3;ofVI1PDZ5NkO0
SGC-7901 NYDBbI16SXCxcITvd4l{KEG|c3H5 NXzGfG5jOTEQvF2= NIHtTJUzPGh? MlrVdJJwdW:2ZYOgeIhmKEOJSVmtbY5pcWKrdHXkJINmdGxiZ4Lve5RpKGmwIGPHR{04QTBzIHPlcIx{ NX:xUWhVOjR2NUS0PFg>
k1735 MoTvRZBweHSxc3nzJGF{e2G7 M3rYVFIx6oDLzszt NWPrRVZYPGh? NIXD[nZqdmirYnn0d:KhW2GubX;u[Yxt[S2rbnT1Z4VlKGGyb4D0c5Nqew>? NYfxbWRMOjR2NUGxNVY>
HaCaT  MorDRZBweHSxc3nzJGF{e2G7 MlHNNVAx|ryP MmWxNYg> NV;aTmlH[my3boTzJHVXSi2rbnT1Z4VlKGGyb4D0c5NqeyCrbjDIZWNiXCClZXzsdy=> M{XTNFI1OzV4OUm3
podocytes NICxUXhCeG:ydH;zbZMhSXO|YYm= NF;BXJEzODEQvF2= MXO2bC=> M4fWd4lvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KDNuND3ES2U> NF\0epYzPDN|N{e3Oy=>
 KB NHvvXmVCeG:ydH;zbZMhSXO|YYm= NX3YboQzPTEQvF2= MUmyOIg> NUTNVnVYcW6qaXLpeJMhVGmlbz3BMYlv\HWlZXSgZ4F{eGG|ZT2zJIFv\CCSQWLQJIFkfGm4YYTpc44> MkHCNlQ{Ozd2OUK=
 HepG2  M2H4e2Fxd3C2b4Ppd{BCe3OjeR?= M3fYVFEx|ryP NF;iSY8zPGh? NWW2NIFYemWmdXPld{B3cW2nboTpckBkdGWjdnHn[UBk[XW|ZXSgZpkhVFCV NGnlWVUzPDN{NUixOi=>
fetal rat lung fibroblasts  Mn22T4lv[XOnIFHzd4F6 M4XZfVgx|ryPwrC= NYTKWXNIOWh? MVfpcohq[mm2czDDZZNx[XOnLUOgZYN1cX[rdIpCpC=> MojFNlQ{OTRzM{W=
PDL fibroblasts MkPuT4lv[XOnIFHzd4F6 M3XXUVgx|ryPwrC= Mm\WNYg> MYDpcohq[mm2czDDZZNx[XOnLUOgZYN1cX[rdIpCpC=> NIHZboszPDNzNEGzOS=>
MB49 MUDBdI9xfG:|aYOgRZN{[Xl? NWLWOXVjOjEQvF2= M3OxUVFp NF;ueVJz\X[ncoPld{BEVS2rbnT1Z4VlKGOnbHyg[IVifGh? MUmyOFI5OjR|Mx?=
5637 MkH1RZBweHSxc3nzJGF{e2G7 MX[yNO69VQ>? NHXnfXgycA>? M3vySZJmfmW{c3XzJGNONWmwZIXj[YQh[2WubDDk[YF1cA>? NYrseXByOjR{OEK0N|M>
A549  NGPyNplCeG:ydH;zbZMhSXO|YYm= NY\lUYdlOTByzszN MYi0PIg> MnrRd5VxeHKnc4Pld{B1cGViYYDvdJRwe2m|IHPheZNm\CCkeTDwbZBmemmwZdMg NXTu[|JGOjR{N{KyNFE>
MCC-2 NXjUe5VTSXCxcITvd4l{KEG|c3H5 NUPZcXpbOjBizszN M1fHRVZp MWnEUXNQ NFrYc5JjdG:la4OgbY5lfWOnZDDifUB{fGG3cn;zdI9zcW6nIHHwc5B1d3OrczDj[YxtKGSnYYTo MYGyOFI3OjZ3OB?=
ADF MlKwRZBweHSxc3nzJGF{e2G7 NH;kdZM1OM7:TR?= M2TS[|Zp NFL2cppqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSClaHXtc5Rp\XKjcImgdIx2eyCcblPsNi=> MWWyOFIzQDJ|Mh?=
 U373  NHW1b45CeG:ydH;zbZMhSXO|YYm= NEnXVHY1OM7:TR?= MXq2bC=> NYr6bmRDcW6qaXLpeJMh[XCxcITvd4l{KGmwZIXj[YQh[nliY3jlcY91cGW{YYD5JJBtfXNiWn7DcFI> NYG4O5VyOjR{MkiyN|I>
RKO-HIPK2i MU\BdI9xfG:|aYOgRZN{[Xl? NULqNoxCPDEQvF2= NG[wbJM3cA>? NIi4RZRqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSClaHXtc5Rp\XKjcImgdIx2eyCcblPsNi=> NYPwR|dQOjR{MkiyN|I>
HEC-1B NXjROlJHSXCxcITvd4l{KEG|c3H5 MVSyNO69VQ>? NXW5NmZ6OWh? MULy[YR2[2W|IGTQMYlv\HWlZXSgZZBweHSxc3nzxsBk[XOyYYPlMVMh[W6mIHPhd5Bie2VvOR?= M1K2WVI1OjF|M{W4
4T1 MUDD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MmTPNk42NTFyzszN MV60bC=> NHL3PY5FVVOR M1XnWJJme2O3ZYOgeIhmKGO7dH;0c5hq[2m2eTDv[kA1XDFiY3XscJMhcW6mdXPl[EBjgSCVUFTUJIlvKGFiY3;uZ4VvfHKjdHnvckBl\XCnbnTlcpQhdWGwbnXy NGD1T5UzPDJyNkG2NS=>
OS  MlzJRZBweHSxc3nzJGF{e2G7 M4W2eFIx|ryP MUS0bC=> M1rPSYlvcGmkaYTzJJRp\SClZXzsJIRm[XSqIHPheZNm\CCkeTDQSHQ> M1LMbVI1OjB2OUO3
RPE MlqwRZBweHSxc3nzJGF{e2G7 NXT3N2R[OTByzszN MUm0PIg> M1XuWpBienSrYXzsfUBqdmirYnn0d{B1cGViY3HsdIFqdi1zIHHu[EAuOiCjY4TpeoF1cW:wIHHzJJdmdGxiYYOgeIhmKGOjc4Dhd4Uh[WO2aY\heIlwdg>? NWDvflF7OjR{MEKwOVI>
UD29a M3rTN2Fxd3C2b4Ppd{BCe3OjeR?= Mn\hOVDPxE1? Ml7qNlRp MknpbY5pcWKrdIOgeIhmKGOnbHyg[IVifGhiY3H1d4VlKGK7IF7VWFM> NVrOdmlyOjRzOUC1O|Q>
SH-SY5Y  MXHBdI9xfG:|aYOgRZN{[Xl? NUDrdIZUOTEQvF2= MUOyOIg> NYCxSYJF[XS2ZX71ZZRmeyClYYPwZZNmKGGldHn2ZZRqd25iYX7kJINmdGxiZHXheIghcW6mdXPl[EBjgSCKTlWtNmRI NGHaRpczPDF2NUS2Ny=>
HeLa  NIj4PJBCeG:ydH;zbZMhSXO|YYm= NGjvSGUyOC9{MN88US=> MlS2NlRp NUHWZ5NqcW6qaXLpeJMhfGinIHHjeIl3cXS7IH;mJJRp\SCvYXrvdol1gSCxZjD0bIUhdWWvYnXyd{Bw\iC2aHWgZ4F{eGG|ZT3mZY1qdHl? NGj2VIQzPDF|N{K2Oi=>
SCCVII  MWfBdI9xfG:|aYOgRZN{[Xl? NFTJTVIzPc7:TR?= M2j6[FFp NGrnbFFqdmirYnn0d{B1cGViY3XscEBscWyuaX7nJIFnfGW{IHThd4F1cW6rYh?= NY\T[2xjOjRzMk[0OlQ>
RAW 264.7 MnXqRZBweHSxc3nzJGF{e2G7 MoXGNlDPxE1? NYe3W3p4OTiq M2rVeIlv[3KnYYPld{BNSzNvSVmv{tIu[WO2aX6gdoF1cW9iY3;tdIFz\WRidH:gSWNVXi2PT2OgeJJm[XSvZX70JI9vdHl? MmW1NlQyOTZ5MEe=
A549  NVnSPY97SXCxcITvd4l{KEG|c3H5 M3LTd|IvPc7:TR?= MVeyOIg> MXrk[YNz\WG|ZYOgc5Jq\G:waX6tbY5lfWOnZDDheZRweGijZ4mgZZMhf2WubDDhcoQhVG:|czDv[kDPnM,KbTDhcJNwKG:lY4XydoVlKGS3cnnu[{BifXSxcHjh[4lkKHC{b3Pld5M> NHni[FUzPDFyMkWyNi=>
UM-SCC-10A  NGPGfIVCeG:ydH;zbZMhSXO|YYm= MYe1NOK2VQ>? NXf2XJljOmh? M3nxfJJm\HWlZYOgZZBweHSxc3nzJIlv\HWlZXSgZpkhcGmpaD3kc5NmKGm|b3HsZY51d2yjY4TvcoU> MoD0NlQxQTh5NUO=
BGC-823 MYjBdI9xfG:|aYOgRZN{[Xl? M{PPU|ExKM7:TR?= M12z[lI1cA>? M1fBdJJm\HWlZYOgeIV1emGwZILpcoUucW6mdXPl[EBieG:ydH;zbZPDqA>? NELiO48zPDB7OEWxNS=>
Nalm-6  M2TXe2Fxd3C2b4Ppd{BCe3OjeR?= M3LZOFIx|ryP MoTJOIg> NXr6bFJTcW6qaXLpeJMh[2G|cHHz[U05KGGwZDDjZZNx[XOnLUOgZYN1cX[jdHnvckBidmRiUFHSVE0yKGOuZXH2ZYdm NUjTcWlmOjRyM{m5Olc>
KHOS  NV33WY52SXCxcITvd4l{KEG|c3H5 NE\hZWc1OM7:TR?= NV\HXJI4OjSq M2X2foJtd2OtczD0bIUhcW6lcnXhd4VlKGOuZXH2ZYdmKG:oIHPhd5Bie2VvMzDhcoQhWEGUUDDpcoR2[2WmIHL5JGJDVUR|wrC= MmTYNlQxOjV|NkG=
G292 NFzTWpFCeG:ydH;zbZMhSXO|YYm= MoP5OFDPxE1? NHvOblYzPGh? M1vCUoJtd2OtczD0bIUhcW6lcnXhd4VlKGOuZXH2ZYdmKG:oIHPhd5Bie2VvMzDhcoQhWEGUUDDpcoR2[2WmIHL5JGJDVUR|wrC= NVThRlc3OjRyMkWzOlE>
MG-63 NVzBeXRCSXCxcITvd4l{KEG|c3H5 NIiwb3k1OM7:TR?= NV70RnRFOjSq M1LUVIJtd2OtczD0bIUhcW6lcnXhd4VlKGOuZXH2ZYdmKG:oIHPhd5Bie2VvMzDhcoQhWEGUUDDpcoR2[2WmIHL5JGJDVUR|wrC= NFPubXQzPDB{NUO2NS=>
EBV-transformed B cells M2iyTWFxd3C2b4Ppd{BCe3OjeR?= NYLXclNlOjEQvF2= MlS4Nog> NVXaNZNsTE2VTx?= M2racYJtd2OtczDhcpRqNUOGOECgZY5lKGGwdHmtR2Q5PiCjboTpZo9lgS2rbnT1Z4VlKGGyb4D0c5Nqew>? MVWyOFAxQDZ{OB?=
IM-9 B MVHBdI9xfG:|aYOgRZN{[Xl? NWnZUXptOjEQvF2= M1:3dlJp MlTzSG1UVw>? Moe0Zoxw[2u|IHHueIkuS0R6MDDhcoQh[W62aT3DSFg3KGGwdHnic4R6NWmwZIXj[YQh[XCxcITvd4l{ MXGyOFAxQDZ{OB?=
CNE1 MkTERZBweHSxc3nzJGF{e2G7 MlSwNlDPxE1? MnnQOFhp NVjoUHNZ[myxY3vzJGxMNUFvaX7keYNm\CCjcH;weI9{cXN? MoDFNlM6QDVyMkm=
CNE2 NXfWRnAySXCxcITvd4l{KEG|c3H5 Mnu2NlDPxE1? MmWzOFhp M4m4TYJtd2OtczDMT{1CNWmwZIXj[YQh[XCxcITvd4l{ MYKyN|k5PTB{OR?=
HL-60 M37q[mFxd3C2b4Ppd{BCe3OjeR?= NXfR[mM{PTEEtV2= M13oWFFp M4jXRmROW09? M4m1VYlvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KEKDMUS1 Mn3ENlM6PDh5NUG=
L929 M2TBTmFxd3C2b4Ppd{BCe3OjeR?= MnW0NU4zPeLCk{ZCpO69VcLi NF;Nem4zPGh? MYHheYdu\W62czDUUmbPuS2rbnT1Z4VlKG6nY4LvdJRwe2m|IHHu[EBifXSxcHjh[5k> MVSyN|k1OTd4OR?=
Jurkat MX3D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NW\Id3pFOs7:TR?= MmraOIg> MYDy[ZZmenOnczDndo94fGhiaX7obYJqfGmxbjDhcoQh|rJvY3H0[Y5qdiCmZXPy[YF{\SCkeTDIV{1CW0F? M1nlfVI{QDl4ME[x
RAW264.7  M2HWRmFxd3C2b4Ppd{BCe3OjeR?= NEP3N2MyOCEQvF2= Mn:4NlRp NV3mbW1I\GWlcnXhd4V{KHSqZTDhdI9xfG:|aYOgbY5lfWOnZDDifUBISQ>? M2LKVlI{QDJyMkCz
A431  M2H4WmtqdmG|ZTDBd5NigQ>? MnznOFDPxE1? MlrYNog> M2PCcIJtd2OtczDmbZNmfGmwLXnu[JVk\WRiY3zlZZZi\2Vib3[gZ4F{eGG|ZYOgZY5lKFCDUmC= NWXuOolzOjN6MECwOVg>
Jurkat MUHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NV\OU4ttOjVvMUCw{txO M4\qVFZp MXzpcohq[mm2czD6MWZCNUOPSz3pcoR2[2WmIHPlcIwh\GWjdHi= MUmyN|k{OzV|Mh?=
COS-7  NVvSXINUTnWwY4Tpc44hSXO|YYm= M1X1dVUxyrWP NILtOVkzPGh? MmjXZYZn\WO2czD0bIUheHKxY3Xzd4lv\yCxZjDBWG4yeyC5aYToJJBwdHmTIITyZYN1ew>? NIDt[3IzOzl|M{KwPC=>
CAL27 MoX2RZBweHSxc3nzJGF{e2G7 NHHkbHoyOCEQvF2= NX\IN5BpOmh? MUPzeZBxemW|c3XzJGN2ei2QUIOtdoVlfWOnZDD2bYFjcWyrdImgZpkhfXBidH:gPVAm M3nvUlI{QTF5M{m2
THP-1  NFHGXlJCeG:ydH;zbZMhSXO|YYm= NFzGVW4yOC13MN88US=> NWDNOlZFOmh? Mn7SbY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkhfHKrcITvcIll\Q>? Mm\vNlM6ODB{OUm=
K562 MYjBdI9xfG:|aYOgRZN{[Xl? MVSyNO69VQ>? M3vvUFQ5cA>? M2PNdIlvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KDRvTWW= NF;TWmYzOzh5NkiyOi=>
HL-60 NXzpUG5USXCxcITvd4l{KEG|c3H5 MmjuNVAx|ryP MoWzNlRp MXjpcohq[mm2czDhdI9xfG:|aYOgbY5lfWOnZDDifUBi[mmndHHu[UBlcXSncoDlcoV{yqB? MYOyN|g3PTd5OB?=
HeLa  MVHBdI9xfG:|aYOgRZN{[Xl? NXLhenNuOjEQvF2= M3ywTFJp NUTR[IxocW6qaXLpeJMhTE2PUDDpcoR2[2WmIHHwc5B1d3Orcx?= MlnqNlM5PjN7Nk[=
U251 MUHBdI9xfG:|aYOgRZN{[Xl? M1LtUVIx|ryP NV;SWoJyOjSq NFnDOY1qdmirYnn0d{Bk[XO2aXPpckBqdmS3Y3XkJGczN01icHjhd4Uh[XK{ZYP0JIFv\CCjcH;weI9{cXN? MWWyN|gyPjhzNh?=
HL-60 M4DmcGFxd3C2b4Ppd{BCe3OjeR?= NXftOolPPTEEtV2= M4fnR|Rp NFvjUZNjdG:la4OgeIhmKGOuZXH2ZYdmKG:oIHPhd5Bie2VvMzygMVktKGGwZDDQRXJRKGmwZIXj[YQh[nliNoO= MnfrNlM5ODR5ME[=
Ec-109 NFqy[o1CeG:ydH;zbZMhSXO|YYm= MYWxNEDPxE1? M1HoSVQ5cA>? MoXIdoVxemW|c3XzJHBGNW2nZHnheIVlKEWlLUGwPUBk\WyuIHHwc5B1d3Orcx?= NV22cIlGOjN5OEK2OFE>
RKO M1rmV2NmdGxiVnnhZoltcXS7IFHzd4F6 M1LrWlExKM7:TR?= MXeyOIg> M{CwNIlvcGmkaYTzJJRp\SCmZXPy[YF{\SCxZjDj[YxtKH[rYXLpcIl1gSClYYXz[YQh[nliRFHC M1HXUlI{PzV6ME[0
T98G M1nqWmNmdGxiVnnhZoltcXS7IFHzd4F6 NIDhfW8yNTFyMN88US=> M1ntblI1cA>? NIXnZmNqdXC{b4\ld{Bk\WyuII\pZYJqdGm2eTDjc5Rz\WG2bXXueEB4cXSqIGTT MmHlNlM4Pjl{N{W=
Jurkat NH;5VoRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MmHpNVAxNTJyMN88US=> M2rhTVI1cA>? MYLpcohq[mm2czDIZWE1KGmwZIXj[ZMh[XCxcITvd4l{KGSncHXu[IVvfCCxZjDjc45k\W62cnH0bY9vyqB? NX\KcZFVOjN5M{K0PFE>
Molt-3  NGXHOYFCeG:ydH;zbZMhSXO|YYm= Moj1OVDPxE1? M3nUR|Jp MXPy[YR2[2W|IH3lcIF1d26rbj3pcoR2[2WmIHHwc5B1d3Orcx?= M2LqcFI{PzJ3MEGz
hMSC12 NEXxdnRCeG:ydH;zbZMhSXO|YYm= MnnyNVAx|ryP M1T1SFRl MW\pcohq[mm2czDvd5Rmd2enbnnjJIN2dHS3cnWtbY5lfWOnZDDj[YxtKGSnYYToJIFv\CClYXzjbYZq[2G2aX;u NVHqb4xMOjN4NUe4NlI>
HM7  M2j4O2Fxd3C2b4Ppd{BCe3OjeR?= MW[yNO69VcLi M1zGfVFp M1\YW4Jtd2OtczDhdIlkfWyjcnXuJGEh[WOndHH0[U1qdmS3Y3XkJINie3Cjc3WtN{Bi[3SrdnH0bY9vKGGwZDDQRXJRKGOuZXH2ZYdm M1\Ie|I{PTh|NEGy
Hep-2  Mk\MRZBweHSxc3nzJGF{e2G7 MmPiNlDPxE4EoB?= M1jzW|I1cA>? MVLEUXNQ MnzVZYxt\X[rYYTld{B1cGViZHXjdoVie2Vib3[gZ4VtdCC4aXHibYxqfHliaX7keYNm\CCkeTDzbYxq[mmwaX6= MofnNlM2QDByM{K=
HSCs MUXBdI9xfG:|aYOgRZN{[Xl? M2rIdlUx|ryP M3f0ZlI1cA>? NXLSd|JyTE2VTx?= MYrpcohq[mm2czDubYxwfGmwaXKtbY5lfWOnZDDEUmEh\GGvYXflJIlv\GmlYYTl[EBjgSCSQWLQJINt\WG4YXfl NWn4fYJiOjN2OUm4O|Q>
HL-60  NYLGOYc5S3m2b4TvfIlkcXS7IFHzd4F6 NYr5TnN4OjEQvF5CpC=> M2TUc|I1cA>? NXy5WJp4emWmdXPld{B1cGViY4n0c5RwgGmlIHXm[oVkfCCxZjDFdpk2 NECzT|YzOzR7NES4NC=>
HA NVvyTXl[SXCxcITvd4l{KEG|c3H5 NV\NZYdSPTEQvF2= M2i2W|I1cA>? MnTad5VxeHKnc4Pld{B1cGViY3zlZZZi\2Vib3[gVGFTWCCjbnSgZ4F{eGG|ZT2zMEAuPyxiYX7kJE06KGmwZIXj[YQh[nliYn;yeIV7d22rYj;TRWhC NUfWWZdJOjN2N{W5OVY>
C666-1 MXTBdI9xfG:|aYOgRZN{[Xl? NGe5bGY2OM7:TR?= MnL3NlRp M4jPeJN2eHC{ZYPz[ZMhfGinIHPs[YF3[WenIH;mJHBCWlBiYX7kJINie3Cjc3WtN{whNTduIHHu[EAuQSCrbnT1Z4VlKGK7IHLvdpRmgm:vaXKvV2FJSQ>? M2jwUVI{PDd3OUW2
Hepa1-6 MVnBdI9xfG:|aYOgRZN{[Xl? MY[1NO69VQ>? M2\pUFJp NF;UNpJqdmirYnn0d{BkfXKldX3pckBidmRicnXzeoVz[XS{b3ytbY5lfWOnZDDhdI9xfG:|aYO= M2Ox[VI{PDR4N{Wz
PLC/PRF/5c Mk\yRZBweHSxc3nzJGF{e2G7 M{ToTlUx|ryP MXuxbC=> MkWxdJJmfmWwdIOgZZBweHSxc3nzJJRzcWepZYLl[EBjgSCFSV6= Ml\UNlM1Ozh6MkS=
HCT116 Mm\wRZBweHSxc3nzJGF{e2G7 NFnKPWsyODEQvF2= MXKxMlVp NFPXUmVqdmirYnn0d{BQey2rbnT1Z4VlKGOnbHyg[IVifGh? NETGVIczOzd2NEO1Ny=>
HCEC M{f0[2Z2dmO2aX;uJGF{e2G7 M4DwVlUx|ryP NHm0Sow4Omh? NXnsbmZ3TE2VTx?= M4fJR5Jme3SxcnXzJI9nKHSqZTDuc5Ju[WxiSFPFR{BxcGWwb4T5dIU> NX:wWmlqOjN5NEKwNVE>
Primary rat cerebral cortical neurons M{j4SWFxd3C2b4Ppd{BCe3OjeR?= MnjYNVAx|ryP NGPNN28ycA>? NUTP[pN{eHKndnXueJMhS2RvaX7keYNm\CCjcH;weI9{cXNiYX7kJINmdGxiZHXheIg> M4\Sc|I{PzRzM{G3
MDA-MB-231  NGXiSHlCeG:ydH;zbZMhSXO|YYm= NUfKZ3k3OjYQvF2= Ml23NlRp NFnTcoFi[nKxZ3H0[ZMh[3m2b4TvfIlkcXS7IHHu[EBkdGWjdnHn[UBw\iClYYPwZZNmNTNiYX7kJHBCWlBiaX7keYNm\CCkeTDS[|M> NH7zXFczPTN|N{W0OC=>
NLRP3-Tet-on-MC/9  Mm\URZBweHSxc3nzJGF{e2G7 M4jvPFExNTRyzszN NGrBVHAyOmh? NHnwU3lifHSnboXheIV{KHSqZTDj[YxtKGSnYYToJINifXOnZDDifUBESVCVLXHzd49kcWG2ZXSgUmxTWDNibYX0ZY51eyCrbjD0bIUhXGW2LX;uJJN6e3SnbR?= NFrDRpgzOzdyM{O4PS=>
KNS42  M4TGZmFxd3C2b4Ppd{BCe3OjeR?= M3O0VlUx|ryP M4LlXlFp M3jDWZJm\HWlZYOgZ4VtdCCmZXH0bEBidmRiY3;tdIxmfGWueTDhZo9tcXOqZXSgZ4F{eGG|ZTCzM|ch[WO2aY\peJkhcW5icnXzdI9ve2VidH:gRWJVNTJ4Mz:ySGcwdWW2Zn;ycYlvKGOxbXLpcoF1cW:w MYOyN|Y6OTF2NR?=
MCF-7  NUnwbJduSXCxcITvd4l{KEG|c3H5 NEX3NFAzOM7:TdMg M2D2fVczcA>? MoPUbY5pcWKrdIOg[ZF2d2xvIHHu[EA1NU:KVD3t[YRq[XSnZDDhdI9xfG:|aYO= MVGyN|Y4PTZ2Mx?=
hCMEC/D3  NYPpfGhFSXCxcITvd4l{KEG|c3H5 M3S3[VI2|ryP MUW3Nog> NELZRphz\WS3Y3XzJGx1gEFiaX7keYNm\CCjcH;weI9{cXN? MVqyN|Y3PTF7OB?=
Jurkat NUXTU5VYSXCxcITvd4l{KEG|c3H5 Mmn2NVIvPS13MN88US=> MWGxbC=> MULkc5NmKGSncHXu[IVvfGy7IIP1dJBz\XO|ZYOgV3BJNWmwZIXj[YQhWGG{LUSgZ4xm[X[jZ3WsJHBCWlBiY3zlZZZi\2VuIFTORUBnemGpbXXueIF1cW:wLDDhcoQhdG:|czDv[kB3cWGkaXzpeJk> MlLTNlM1PDJ7N{[=
CNE-1 MlLFRZBweHSxc3nzJGF{e2G7 NYjHZYRUOjEQvF5CpC=> MXeyOIg> NHG3fGtqdmirYnn0d{BTSURyMEGtbY5lfWOnZDDj[YxtKGSnYYTo MYeyN|QzPjh3MB?=
HONE-1 M3LPdGFxd3C2b4Ppd{BCe3OjeR?= NHXPXmQzOM7:TdMg MUCyOIg> MYPpcohq[mm2czDSRWQxODFvaX7keYNm\CClZXzsJIRm[XSq NVv0cYR{OjN2Mk[4OVA>
astrocytes cell NGX5NWJCeG:ydH;zbZMhSXO|YYm= MWm0NO69VQ>? Mn:5Oog> NVSyeXhKemWmdXPld{Bm[XKueTDhdI9xfG:|aYOgbY5lfWOnZDDifUB{fGG3cn;zdI9zcW6n Mom2NlM1OTF5N{i=
U-937 NI[zUGhCeG:ydH;zbZMhSXO|YYm= M4jZWFEx|ryP M3\ScFMxdWmw MlrSdJJmfmWwdIOgWG5HNWmwZIXj[YQhdmWlcn;weI9{cXN? MYGyN|QyODd2OB?=
MDA-MB-231 MVLBdI9xfG:|aYOgRZN{[Xl? NGj3W3kyODEQvF2= Mmi3NYg> NFLnV4lqdmirYnn0d{B{\W6|aYTpfoF1cW:wIITvJHRTSUmOIIXwc44hVVSGSDDkc5dvNXKnZ4XsZZRqd25? NGDibnYzOzRyOESyPS=>
HeLa  M{PFeWFxd3C2b4Ppd{BCe3OjeR?= NHHyW3AyODEQvF2= NEfCVXMzcA>? MXXicI9kc3NiSmLTMVE2KEmwZIXj[ZMhSXCxcITveIlkKEOnbHygSIVifGh? MnTBNlM{PDRyNEW=
Ec109 M17uRWFxd3C2b4Ppd{BCe3OjeR?= M{DnfVEx|ryP Ml3nOog> M1TodIJtd2OtczDhdI9xfG:2aXOgZ49u[mmwYYTpc44hd2ZiVHH0MXNu[WOQNzDhcoQhemGmaXH0bY9v Mnm5NlM{Ozh3Nki=
H460  NGDzUYZCeG:ydH;zbZMhSXO|YYm= NUjPXoozOTEQvF2= NV7Bb5BXPmh? MnrEZoxw[2u|IHHwc5B1d3SrYzDjc41jcW6jdHnvckBw\iCWYYStV41i[055IHHu[EBz[WSrYYTpc44> M2HEZlI{OzN6NU[4
HeLa  NHf3coNCeG:ydH;zbZMhSXO|YYm= M3T6fFUx|ryP NWDNdZFKOS53aB?= NIHXZ5pi[nKxZ3H0[ZPDqEOqbHHtfYRq[S2rbnT1Z4VlKGGyb4D0c5Nqew>? Mn;qNlM{ODN6MES=
SK-HEP1 NGPrTlhCeG:ydH;zbZMhSXO|YYm= MWWxNFDPxE1? MlPqNYg> NXy5eWR7cW6qaXLpeJMhS3KWMTDhZ5RqfmG2ZXSgZ4F{eGG|ZT2zMEAuPyxiLUisJE06NCCjbnSgdI9tgSiDRGCtdoljd3OnKTDwc4x6dWW{YYPl Mm[xNlM{ODJ4NUC=
QGY7701 NE\lPW5CeG:ydH;zbZMhSXO|YYm= NVTkZnZiOjYQvF2= M4XT[FEvPWh? NEPkdmRqdmirYnn0d{Bi[2O3bYXsZZRqd25ib3[gd5VjNUdzIIDoZZNmKGmwZIXj[YQh[nliRF;YJEsheXWncnPleIlv MV2yN|I1ODB4MR?=
HepG2 NXfXN2VYSXCxcITvd4l{KEG|c3H5 MkKyNlDPxE1? M{PQPVMxdWmw M{nIbIlvcGmkaYTzJJRp\SCnbnjhcoNm\CClZXzsJIRm[XSqIHL5JINwdWKrbnXkJJRz\WG2bXXueEBw\iCjcHnn[Y5qdiCjbnSgWHJCUUx? MW[yN|IzPDJ|OR?=
U87  M1HCUWFxd3C2b4Ppd{BCe3OjeR?= MoL4NlXPxE1? NHq3Oo8zcA>? M4Tx[4Rm[3KnYYPld{Bqe2:uaYH1bZJqfGmpZX7pckApUVOOKT3pcoR2[2WmIHHwc5B1d3SrYzDj[YxtKGSnYYToMEBjfXRibn;0JI5m[3KxdHnjJINmdGxiZHXheIg> NYrpfXo2OjN{Mkm2NlY>
HSC-2 NV\zS3NnSXCxcITvd4l{KEG|c3H5 NEPHNWczPS93MN88US=> NF75bZkycA>? M2jCTolvcGmkaYTzJHNPNTN6LXnu[JVk\WRiY4n0c5RwgGmlaYT5 NUj1NpNUOjNzNUWyOFg>
HSC-4 NF7icIZCeG:ydH;zbZMhSXO|YYm= NXTG[WIxOjVxNUFOwG0> NHnOTpgycA>? NXSwZnF4cW6qaXLpeJMhW05vM{itbY5lfWOnZDDjfZRwfG:6aXPpeJk> NGPRXWwzOzF3NUK0PC=>
CL-1 NWHSN4RjSXCxcITvd4l{KEG|c3H5 MX2yNO69VQ>? MnfuNYg> NYnhc2dY[myxY3vzJG9RPDR7IHnu[JVk\WRiY3XscEBl\WG2aB?= MYeyN|E{OTd6Mh?=
MEL MnfHRZBweHSxc3nzJGF{e2G7 NHrvdnIzOM7:TR?= NWfycZM3OjSq NWG2XYdPTE2VTx?= M4TafIlueGGrcnXzJHAzYDdvaX7keYNm\CCPRVygZ4VtdCCjcH;weI9{cXN? MlHaNlMxOTR6OEe=
Bel-7402  M4TVXmNie3Cjc3WgRYN1cX[jdHnvckBCe3OjeR?= NF7NNlc2OM7:TR?= MVGybC=> MmDybY5pcWKrdIOgVGNGNWmwZIXj[YQh[W6xaXvpdy=> MYKyN|AxQDd2Mh?=
Eca-109 NVfuXGVmSXCxcITvd4l{KEG|c3H5 MVSyOe69VQ>? NXjoTlhUOzCvaX6= NYrIeJFPcW6qaXLpeJMhSkpvQkGxMYlv\HWlZXSgZ4VtdCCmZXH0bC=> NYi3SpJoOjNyN{[5Olc>
MEL M1Hab2Fxd3C2b4Ppd{BCe3OjeR?= M4rZN|Ix|ryP MWWxbC=> NUDFT|JUTE2VTx?= NGXXPVRqdXCjaYLld{BROlh5LXnu[JVk\WRiTVXMJINmdGxiYYDvdJRwe2m| M{fvNVI{ODF2OEi3
Bel-7402  Mm\BRZBweHSxc3nzJGF{e2G7 M1rLfVUx|ryP MkDtNog> NUDuV3ZVcW6qaXLpeJMhWEOHLXnu[JVk\WRiYX7vbYtqew>? NGrDNVAzOzByOEe0Ni=>
L929 MXrGeY5kfGmxbjDBd5NigQ>? Mnv1Nk42|ryP M3fmW|Fp MXHpcoNz\WG|ZYOgVmlROSCneIDy[ZN{cW:wIHHu[EBmgGGlZYLiZZRm\CCWTldOtU1qdmS3Y3XkJI1qfG:laH;u[JJq[WxiZInz[pVv[3Srb36gZY5lKFKRUzDwdo9lfWO2aX;u M1;ORVI{ODByNUG4
RCC  NXLsTWRqS2WubDDWbYFjcWyrdImgRZN{[Xl? MX2xNFDPxE1? MX[yOIg> MW\y[YNwfmW{ZYOgeIhmKH[rYXLpcIl1gSCxZjDj[YxteyCneIDvd4VlKHSxIEG1[E1RT0p{ M2P0dFIzQTlzNEm0
NB2a/d1 MUPBdI9xfG:|aYOgRZN{[Xl? MlfSNVAx|ryP MnSzO|Jp MoLHZZR1\W63YYTld{B{fGG3cn;zdI9zcW6nLXnu[JVk\WRiY3HzdIF{\SCjY4Tpeol1gSxiUFHSVEwh[W6mIITheUBkdGWjdnHn[S=> M{G5PVIzQTh6NUSx
T cell NVrL[GV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\ISlI2NTFyMN88US=> MYWyOIg> MUDkc5NmNWSncHXu[IVvfGy7IHnubIljcXSnZDDUJINmdGxicILvcIln\XKjdHnvckBu\WSrYYTl[EB1cHKxdXfoJJRp\SClbz3zeIlufWyjdHnvckB4cXSqIHHueIkuS0R|IHHu[EBidnSrLVPENlg> MVWyNlk5OjV|OB?=
K562 NVXjeHpwSXCxcITvd4l{KEG|c3H5 Ml3BNVAx|ryP MVyxbC=> MWXicI9kc3NiQXLuc4Jifmm|Y4XtxsBHNWmwZIXj[YQh[XCxcITvd4l{ MofNNlI6PzJ|N{K=
Jurkat  MXfBdI9xfG:|aYOgRZN{[Xl? MXm0NO69VQ>? M3TL[|Fp NIrIOlBi[m:uaYPo[ZMhTmG|TD3pcoR2[2WmIHPhd5Bie2ViYXP0bZZifGmxbjDhcoQh[2WubDDk[YF1cA>? M37mZlIzQTR{N{O4
BGC-823 Mon5RZBweHSxc3nzJGF{e2G7 NF;BOm8yODEQvF2= MUCxbC=> NFHzWWtx[XK2aXHscJkhemW|Y4Xld{Bk\WyuczDh[4FqdnO2IHThcYFo\SCxZjDkZYllgmWrbh?= M4C3N|IzQTJ4NUS1
Hep3B NXjUelRLSXCxcITvd4l{KEG|c3H5 M4rrXVUx|ryP NX[5bZpvOWh? NHyxNpBjdG:la4OgZZBweHSxc3nzJIlv\HWlZXSgZpkhUEWJQ4O= M{G0PFIzQTJ|MUW0
LLC-PK1 NGDnU|hCeG:ydH;zbZMhSXO|YYm= MWqyNO69VQ>? NYLMWGlROWh? M1y5[pBz\X[nboTzJINqe3CuYYTpck1qdmS3Y3XkJIRm\3KjZHH0bY9vKG:oIFH0[|UtKGKnY3zpck0yNCCjbnSgRZRoOTJicILveIVqdnN? MUiyNlg6PjB|Nx?=
A549 MYjBdI9xfG:|aYOgRZN{[Xl? M3LKdFUx|ryP M2fFelFp MWLicI9kc3NidHjlJGJCUS2rbnT1Z4VlKGGyb4D0c5Nqe8Li M32xdVIzQDh5MkG1
SGC-7901  M3TCTmFxd3C2b4Ppd{BCe3OjeR?= M2LrNlEx|ryP MYmyOIg> Ml7RbY5pcWKrdIOg{tIt|rJvZHnt[ZRpgWyjY4L5cJNpcWuxbnnuMYlv\HWlZXSgZZBweHSxc3nzxsA> Mlz6NlI5PDh3OUe=
DM6 M3rhRWFxd3C2b4Ppd{BCe3OjeR?= MojNNVAx|ryP MkHLO|Jp NY\LUHNp[myxY3vzJIJwfGhiRULGMVEh[W6mIFWySpRzNW2nZHnheIVlKGO7dH;0c5hq[2m2eR?= MV2yNlgzPTN{OB?=
MCF-7, MDA-MB-468, Caco-2 NHrIT|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWq1NO69VQ>? MnLTOFhp M13vN4lvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDpcohq[mm2aX;uJIlv\HWlZXSgZpkhe2Gyb37pci=> MnPqNlI5ODB7Nki=
A2750  NU[1bJEySXCxcITvd4l{KEG|c3H5 NEHrW3kzOM7:TR?= M1u3U|Jp NILMO3RFVVOR NET5XXdjdG:la4OgZ4F{eGG|ZTDjcIVifmGpZTDkeZJqdmdiaHXs[Y5idGmwIITy[YF1dWWwdDDhcoQhemWmdXPld{BifXSxcHjh[4lkKGOnbHyg[IVifGh? MVmyNlc5PDN4Mx?=
U87  M4TaWmFxd3C2b4Ppd{BCe3OjeR?= NXnhNoJlOjEQvF2= NXS0c2U1OjSq M2S1fZJm\HWlZYOgeIhmKGGyb4D0c5NqeyC{YYTlJIlv\HWlZXSgZpkhWEyDQh?= NEXUeIszOjd5OEe4NC=>
HT1080 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWC1NO69VQ>? M3H3Z|dl MmrmbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHnubIljcXSrb36gZ4F2e2WmIHL5JINwdWKrbnXkJJRz\WG2bXXueEBw\iCGQ1GgZY5lKE:PUB?= MUCyNlc1ODl6NB?=
A549  MYnBdI9xfG:|aYOgRZN{[Xl? MX[1NO69VQ>? MkHRNog> MlK2dIFzfGmjbHz5JIRm[3KnYYPld{B{d2SrdX2gd4Vt\W6rdHWtbY5lfWOnZDDhdI9xfG:|aYO= MWGyNlczOThyNB?=
Primary OPC M{nNW2Fxd3C2b4Ppd{BCe3OjeR?= MUWx{txO NFfiXXA3cC9{NHi= NXzlTmhKemWmdXPld{B1cGVicHXyZ4VvfGGpZTDv[kBk\WyuczDpckBm[XKueT2gZY5lKGyjdHWtZZBweHSxc3nzM45m[3Kxc3nz NFS1[pQzOjdyN{O4OS=>
PMNs NYLTZoI4SXCxcITvd4l{KEG|c3H5 NHH0WGg1OM7:TR?= NHv1SVM3cA>? M3HrN2ROW09? NIWwb4Jz\X[ncoPl[EB1cGViYX3veY51KG:oIHPs[YF3\WRiY3HzdIF{\S1|IITvJI5m[XJidnXobYNt\SCuZY\lcJM> NYnifZpiOjJ4OUK1O|c>
A549  MYPBdI9xfG:|aYOgRZN{[Xl? NHnwS4c2OM7:TR?= NVL0SGdHOWh? M1rQfJBz\X[nboTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KEKjb3j1c5Nq\GViSR?= MlHLNlI3QDd4M{W=
AGS MYXBdI9xfG:|aYOgRZN{[Xl? M4Pz[VIx|ryP MXmxNog> MXTpcohq[mm2czD0bIUh[WO2aY\heIlwdiCxZjDwdo8u[2G|cHHz[U0{KGmwIILld5BwdnOnIITvJJRp\SCHdF;BZ{BnemGldHnvci=> M2\FOFIzPjh5M{m4
shC9  MXzBdI9xfG:|aYOgRZN{[Xl? MkDZNVDPxE1? NEDybW0yPmh? NXfwS4t6[my3boTzJHNJUCCneIDy[ZN{cW:wIHnuJJNpSzliY3XscJMh\Xiyb4Pl[EB1dyCnaYTo[ZIhWEFib4KgUHBE M37kXFIzPjRzMEm0
primary MEFs NGLCXG5HfW6ldHnvckBCe3OjeR?= MYKxNog> M1\peeKhcW6lcnXhd4V{KGW2b4Dvd4ll\S2rbnT1Z4VlKG2rdH;jbI9v\HKrYXygcYVu[nKjbnWg[IVxd2yjcnn6ZZRqd25? NFPZTFEzOjZzM{e2Oy=>
3T9 MEFs M3LxSmZ2dmO2aX;uJGF{e2G7 NYrDOYQ3OT[q NHe3NWdqdmO{ZXHz[ZMh[3m2b3Podo9u\SClIILlcIVie2ViYX\0[ZIh\XSxcH;zbYRmNXS{ZXH0cYVvfA>? NEXRb2IzOjZzM{e2Oy=>
3T9 MEFs NVLJ[WhHTnWwY4Tpc44hSXO|YYm= MV2xPIg> NXfYcnpzfXC{ZXf1cIF1\XNiaX7peIlifG:{IHPhd5Bie2VvOTDieZQh\G:5boLl[5Vt[XSnczDl[oZm[3SxcjDjZZNx[XOnczDh[pRmeiCndH;wc5Nq\GVidILlZZRu\W62 MVOyNlYyOzd4Nx?=
MDA-MB-231  Mme3RZBweHSxc3nzJGF{e2G7 NE[5ZmMzOM7:TR?= NYrscJl7PGR? MVPy[YR2[2W|IITo[UBk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JI1mfG[xcn3pckB1emWjdH3lcpQhf2G|IIPp[45q\mmlYX70cJk> NWnOS|lnOjJ3OUO0OFE>
C6  MkDmRZBweHSxc3nzJGF{e2G7 Mkj5NVDPxE1? M{PCTVI1cA>? NGXGSpJjdG:la4OgeIhmKHO3cIDy[ZN{cX[nIHXm[oVkfCCxZjD0bIUheGWydHnk[UBwdiC4aXHibYxqfHl? M37IblIzPTh6OUiw
HL-60  NUD4U4g{SXCxcITvd4l{KEG|c3H5 NVrYZm5bOTByzszN MlLuNlRp NI\MdG5qdmirYnn0d{B1cGViY3XscEBieG:ydH;zbZMhe2WuZXP0[YQhMCtrLX3lcpRpgWxizsKtLFHjjpJ4KT3kbYdtfWOxcInyZY5we2mmZdMgOS=> NXqwXFRUOjJ3NE[2Olk>
HL-60 MWLBdI9xfG:|aYOgRZN{[Xl? M{HC[lExNThyzszN NHzVPYw1cA>? M4TqVIlvcGmkaYTzJHRIUFFvaX7keYNm\CClZXzsJIFxd3C2b4Ppd:Kh M1;CVlIzPTJ|MkK5
BCC NH\DcmNCeG:ydH;zbZMhSXO|YYm= M33qPFUx|ryP MU[xbC=> NVGyRYNDcW6qaXLpeJMhTEGWUz3t[YRq[XSnZDDndo94fGhiaX7obYJqfGmxbh?= MmrSNlI2OTl2M{[=
RAW 264.7 M1jMNGFxd3C2b4Ppd{BCe3OjeR?= M{nnOVUxNzFyMN88US=> NGjPd3kycA>? NYrJSJZm[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5pcWKrdIOgSG9PNWmwZIXj[YQhelKQQTDjcIVifmGpZR?= M1jFVVIzPDlzNEK2
K562 NIn1OJJCeG:ydH;zbZMhSXO|YYm= MW[yOe69VQ>? NYXEbJFTOmh? NH\tb5FxemW4ZX70d{BieG:ydH;zbZMhcW6mdXPl[EBjgSClbz30doVifG2nboSge4l1cCCjbYXy[Y5{cW5iRzDhcoQhXFKDSVy= NGCzS4ozOjR6M{e3Oy=>
SGC-7901 Mn;1RZBweHSxc3nzJGF{e2G7 MXSyNEDPxE4EoB?= Mn7iNog> NIDZRYdifHSnboXheIV{KEh{T{NCpI9zKFSQRjFOtU1qdmS3Y3XkJINmdGxiYYDvdJRwe2m|IHHzJJdmdGxiYYOgZ4F{eGG|ZT2zJIFkfGm4aYT5xsA> Ml\NNlI1PzF3OEm=
PC3 NWX3WZB[SXCxcITvd4l{KEG|c3H5 MYKxNO69VQ>? NEKxVWE1cA>? MYLjc5VvfGW{czDmcIF3d2OxeHnkMYlv\HWlZXSgZ4F{eGG|ZT3y[YxifGWmIHHwc5B1d3Orcx?= MUiyNlQ4OTl5NB?=
SMMC-7721 NFvCdVhCeG:ydH;zbZMhSXO|YYm= M2faSFUx|ryP NVnxcW8yPDiq M1\NdoF1fGWwdXH0[ZMhd1SULXnu[JVk\WRiYYDvdJRwe2m| M13ad|IzPDZ3OEOz
HeLa  NWOxSJdKSXCxcITvd4l{KEG|c3H5 NWftZoJPPTEEoN88US=> M1jVd|QwQGh? NVi0fmV2cW6qaXLpeJMhW1SVLXnu[JVk\WRibHH0[U1xcGG|ZTDhdI9xfG:2aXOg[ZZmdnS| MUSyNlQ3ODVyNB?=
HeLa  NW\tRlAySXCxcITvd4l{KEG|c3H5 MUW1NOKh|ryP M{LjfFFp MojCd5VxeHKnc4Pld{B1cGViRmLBVE1qdmS3Y3XkJIFk[3WvdXzheIlwdiCxZjDhco5mgGmwIG[gdI9{cXSrdnWgZ4VtdHN? M2HP[|IzPDR7NESw
T47D  MU\BdI9xfG:|aYOgRZN{[Xl? Ml7UNVAx|ryP MVqxbC=> NGLjfpNjdG:la4OgeIhmKGenbnXyZZRqd25ib3[gSU1k[WRxQ2TGNkBjgSCVVGO= MV[yNlQxOTF4OB?=
HeLa  MkHIRZBweHSxc3nzJGF{e2G7 NYW3WI5XOzEQvF2= M{LOblRp M1L3VOKhcW6lcnXhd4V{KHSqZTDn[Y5memGuIHPlcIwhfmmjYnnsbZR6KDR6IHigZYZ1\XJicHjveI9lgW6jbXnjJJRz\WG2bXXueOKh M1v4[lIzOzl2MkS4
HCC NITXXJVCeG:ydH;zbZMhSXO|YYm= M3X5blIxKM7:TdMg NGDQclEzcA>? MY\heJRmdnWjdHXzJJRp\SCGSFGgbY5lfWOnZDDhZ5RqfmG2aX;uJI9nKFCDUmC= M4\iV|IzOzR{N{Oy
mESCs M1fJZ2Fxd3C2b4Ppd{BCe3OjeR?= NU\QZY9rOi53zszN NEHCS2kzcA>? M4DPdolvcGmkaYTzJJRp\SCQYV[tcYVlcWG2ZXSgZ4F{eGG|ZTDhZ5RqfmG2aX;u NV\MTIljOjJ{OEWyO|Q>
EMT-6  MmmwR5l1d3SxeHnjbZR6KEG|c3H5 MVyxNFDPxE1? NWXlT|V7OWh? NX\QWWx5eGG{dHnhcIx6KGKub3Pr[YQh[2WubDDk[YF1cCCrbnT1Z4VlKGK7IIPpdoFu\XOrbnW= NF7wb4IzOjJ3MUmyNS=>
MCF7 NHnhdG1CeG:ydH;zbZMhSXO|YYm= NX34O3h3PTEEoN88US=> MlfsNYg> MYrpcohq[mm2czDQRUBi[3SrdnH0[YQh[2G|cHHz[U0{NCBvOTygZY5lKHCxbImoRWRRNXKrYn;z[UkheG:ueX3ldoF{\Q>? NIW3RnczOjJ{M{O0OS=>
K562 MYXBdI9xfG:|aYOgRZN{[Xl? NVO1SGc3OjBizszNxsA> MnviOFhp NXr6flVQTE2VTx?= M3jsR4Jtd2OtczDsZZBifGmwaXKtbY5lfWOnZDDpcohq[mm2aX;uJI9nKH[rYXLpcIl1gSCjbnSgZZBweHSxc3nzJIlv\HWldHnvci=> NH3IcZozOjJzNkG1PC=>
Molt4-hyg NHvUSYNCeG:ydH;zbZMhSXO|YYm= NVrBVFFsOTEQvF2= Mkn6NE42cA>? M3uxSIJtd2OtczDmZZJv\XOxbD3pcoR2[2WmIHPhd5Bie2VvMz3sbYtmKGGldHn2bZR6 NHfUTmMzPjJ5NUixNS=>
HeLa NFj6SWJCeG:ydH;zbZMhSXO|YYm= M{eyPFEx|ryP NGG3WYUxNjWq M320cIlvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KHSqZTDjc41jcW6nZDD0doVifG2nboSge4l1cCCpb33pd4lvKE5iYX7kJHRTSUmO NGriRYwzOjF5OU[2NS=>
Jurkat T MlL4RZBweHSxc3nzJGF{e2G7 M17hSlMx|ryP MnryNE42cA>? M1nRdWROW09? NInKPGhjdG:la4OgeIhmKHqrcnHtMYlv\HWlZXSgZZBweHSxc3nz Ml\ENlIyPTl6OUi=
Neutrophil MXjBdI9xfG:|aYOgRZN{[Xl? MYOyNO69VQ>? M2HXSFAvPWh? NGLteIlifHSnboXheIV{KHSqZTDwdo8u[XCxcITveIlkKGWoZnXjeEBw\iCPYWKx NXfVRWJXOjZzOU[4OFQ>
HCT116 M3\CV2Fxd3C2b4Ppd{BCe3OjeR?= M3rTe|UxyqEQvF2= MYeybC=> M2L0cpJmfmW{c3XzJJN6dmW{Z3nzeIlkKGGyb4D0c5NqeyCnZn\lZ5R{KG:oIHPlcIVkd3irYjDhcoQhVlCFLUG2xsA> MmTvNlIyPTl5NUK=
MDA-MB-231  Ml\GRZBweHSxc3nzJGF{e2G7 NF;xZYYzNjVvNz61{txO NFXaUI4zcA>? NHXrOWNqdmirYnn0d{B1cGViY3XscEBl\WG2aDDv[kBOTEFvTVKtNlMyKGOnbHzzJIlv\HWlZXSgZpkhW0SWIHnuJIEh[2:wY3XueJJifGmxbjDk[ZBmdmSnboSgcYFvdmW{ M4DGNVIzOTF3NUK2
LNCaP M4ftfmFxd3C2b4Ppd{BCe3OjeR?= NGLpRXo1OM7:TR?= M3K0VlJp NIe1[FZqdmirYnn0d{BjfXSnaX6gbY5lfWOnZDDj[YxtKGGyb4D0c5Nqew>? MVSyNlEyPDd4NB?=
MB231 MmHURZBweHSxc3nzJGF{e2G7 MYexNFDPxE1? Mle2NYg> NWD2RWxlTE2VTx?= M3vURoFjem:pYYTld{B1cGViaX7keYN1cW:wIH;mJINmdGxiZHXheIgh[nliV1XFNUBqdmirYnn0bY9vNCCWUlHJUEB1emWjdH3lcpQtKGGwZDD0bIUh[2:vYnnuZZRqd25? NXz3XnlKOjJzMUK5OFA>
HCC38  M2ju[WFxd3C2b4Ppd{BCe3OjeR?= NHG4R3MyODEQvF2= M4m4XVFp Mn3OSG1UVw>? MUThZpJw\2G2ZYOgeIhmKGmwZIXjeIlwdiCxZjDj[YxtKGSnYYToJIJ6KFeHRUGgbY5pcWKrdHnvckwhXFKDSVygeJJm[XSvZX70MEBidmRidHjlJINwdWKrbnH0bY9v MXeyNlEyOjl2MB?=
MDA-MB231 MW\BdI9xfG:|aYOgRZN{[Xl? NIHmOm42OMLizszN MnXINlRp NGDhbGVFVVOR MkC2ZYJzd2ejdHXzJIN2emO3bXnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> MnHQNlIyODF|M{W=
LNCaP NF\aVm5CeG:ydH;zbZMhSXO|YYm= MUe1NOKh|ryP MoWxNlRp NF3PeGhFVVOR NXfNblI1[WK{b3fheIV{KGO3cnP1cYlvNWmwZIXj[YQh[2WubDDk[YF1cA>? NVXNOZZ2OjJzMEGzN|U>
HCT116 MYPBdI9xfG:|aYOgRZN{[Xl? NI\qclM2OMLizszN NETLdlgzPGh? NYj4eZFJTE2VTx?= NGjHT|Ni[nKxZ3H0[ZMh[3W{Y4XtbY4ucW6mdXPl[EBk\WyuIHTlZZRp NUXyTGFJOjJzMEGzN|U>
Ishikawa  NHTMV45CeG:ydH;zbZMhSXO|YYm= MYWyOe69VQ>? M1\WVFI1cA>? NF;uO4dz\WS3Y3XzJINmdGxiZHXheIgh[W6mIHHwc5B1d3OrczDpcoR2[2WmIHL5JGJi\iCDMR?= Mk[yNlIxQDh7MUi=
 YD-8  M1raN2Fxd3C2b4Ppd{BCe3OjeR?= NVm0fXFYOTByzszN NWm3W5NZOWh? M3vmfYlvcGmkaYTzJHBNTU9vaX7keYNm\CCjcH;weI9{cXN? MkLXNlIxQDZzOEO=
eosinophil  NIDW[ZhCeG:ydH;zbZMhSXO|YYm= NGnoO206OM7:TR?= MoDlNlRp NFXsOHNqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSCIYYOgZY51cWKxZIpCpC=> NGfqT|kzOjB5OUOzOC=>
L929 MkLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDFVHptOi53zszN NGXCO3QzPGh? NVzDXXZocW6qaXLpeJMhfGinIHX4dJJme3Orb36gc4YheC2yM{igZY5lKE6ILd86RkB1dyCjdXft[Y51KFSQRt8xMYlv\HWlZXSgcoVkem:ydH;zbZMh[W6mIHH1eI9xcGGpeR?= M{DaW|IzODJ5MEm3
YD-8  MVfBdI9xfG:|aYOgRZN{[Xl? NXSzTnk2OTByzszN MnP6NYg> Ml7CZoxw[2u|IITo[UBIWy2KQ3ytbY5lfWOnZDDhdI9xfG:|aYO= M4jRXFIzODJyMEe4
HBx M4G2cmFxd3C2b4Ppd{BCe3OjeR?= NXnjXpF1OjYQvF2= M2K5eVQ5cA>? MmTySG1UVw>? NYHqPHFtemWmdXPl[EBk\WyuIHTlZZRpKGmwZIXj[YQh[nliMz3NRS=> Mn;QNlIxOjByN{i=
U937  MmnpRZBweHSxc3nzJGF{e2G7 MmPwOVDDqM7:TR?= MkLTNYg> M4nRT4lvcGmkaYTzJGhHNWmwZIXj[YQh[XCxcITvd4l{yqB? NVzLRYdrOjF7OUi3N|E>
HL60 MoKxRZBweHSxc3nzJGF{e2G7 M3q0SlQx|ryP MVS0NI1qdg>? M2HYUWROW09? MYficI9kc3NiQl7ER{Bkd22yb4Xu[JMhcW6mdXPlJIV5eG:|dYLlJI9nKHCqb4PwbIF1cWS7bIPldolv\SCjbnSgSG5CKG[{YXft[Y51[XSrb36= NEezT44zOTl6M{K5Oi=>
M-14 NYTwcJJCSXCxcITvd4l{KEG|c3H5 MU[yOe69VQ>? MXqwMlVp NVztcpRWyqCrbnjpZol1eyCkb4ToJJRp\SClcoXk[UBmgHS{YXP0MUBidmRiY3;tdI92dmRvaX7keYNm\CCjcH;weI9{cXN? M3nBN|IyQTV2OUW5
SK-BR-3 MYLBdI9xfG:|aYOgRZN{[Xl? NGPjXHE2OMLizszN NFvxTVgzcA>? MY\icI9kc3NiYYDvdJRwfGmlIFTORUBnemGpbXXueIF1cW:wIHnu[JVk\WRiYomgZ49u[mmwYYTpc44hd2ZiU12tNVY1KGGwZDDyZYRq[XSrb36= NVy1Oo04OjF7MEGzPFY>
MDA-MB-468 MY\BdI9xfG:|aYOgRZN{[Xl? M4nGclUxyqEQvF2= MlPINog> NVX4[oNJ[myxY3vzJIFxd3C2b4TpZ{BFVkFiZoLh[41mdnSjdHnvckBqdmS3Y3XkJIJ6KGOxbXLpcoF1cW:wIH;mJHNONTF4NDDhcoQhemGmaXH0bY9v M3LIUlIyQTBzM{i2

多くの細胞株試験データを見る場合、クリックしてください

体内試験 In vivo Z-VAD-FMK administration has been shown previously to be nontoxic and to prevent apoptosis in animal models. Intraperitoneal HK-GBS injection leads to preterm delivery, and pretreatment with Z-VAD-FMK delays preterm delivery in mice. In OVA-sensitized mice,treatment of z-VAD-fmk inhibits allergen-induced leukocyte infiltration. Systemic injection of the pan-caspase inhibitor z-VAD-fmk immediately before OVA challenge reduced inflammatory cell accumulation, mucus hypersecretion, and Th2 cytokine release in OVA-sensitized/challenged mice. Treatment with z-VAD-fmk blocked terminal differentiation of lens epithelial cells and keratinocytes, the differentiation of monocytes into macrophages, and the differentiation of erythroid progenitors. z-VAD-fmk attenuated allergen-induced airway inflammation and hyperreactivity. Treatment with z-VAD-fmk in vivo also prevented subsequent T cell activation ex vivo[7].

お薦めの試験操作(参考用のみ)

細胞試験:

[6]

+ 展開
  • 細胞株: human granulosa cell lines (GC1a, HGL5, COV434)
  • 濃度: 50 μM
  • 反応時間: 48 h
  • 実験の流れ:

    To validate the efficacy of Z-VAD-FMK, three human granulosa cell lines (GC1a, HGL5, COV434) were treated for 48 h with etoposide (50 μg/ml) and/or Z-VAD-FMK (50 μM) under normoxic conditions. To mimic the ischemic phase that occurs after ovarian fragment transplantation, cells were cultured without serum under hypoxia (1 % O2) and treated with Z-VAD-FMK. The metabolic activity of the cells was evaluated by WST-1 assay. Cell viability was determined by FACS analyses. The expression of apoptosis-related molecules was assessed by RT-qPCR and Western blot analyses.


    (参考用のみ)
動物試験:

[7]

+ 展開
  • 動物モデル: CD1 mice
  • 製剤: dissolved in DMSO, diluted in PBS (final concentration of DMSO < 1%)
  • 投薬量: 10 mg/kg
  • 投与方法: i.p.
    (参考用のみ)

溶解度 (25°C)

化学情報

分子量 467.49
化学式

C22H30FN3O7

CAS No. 187389-52-2
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    Can you suggest an in vivo formulation of S7023 for animal studies?

  • 回答:

    For in vivo study of S7023, The IP formulation is 2% DMSO+35 % PEG 300+2% Tween 80+ddH2O up to 6 mg/ml. The gavage formula is 1%CMC-Na up to 30 mg/ml (suspensions).

  • 質問2:

    What is difference between S7023 & S8102?

  • 回答:

    Unlike S7023, S8102 does not require pretreatment with esterase for in vitro studies. This information was cited from the article: https://www.ncbi.nlm.nih.gov/pubmed/16973565.

Caspaseシグナル伝達経路

相関Caspase製品

Tags: Z-VAD-FMKを買う | Z-VAD-FMK ic50 | Z-VAD-FMK供給者 | Z-VAD-FMKを購入する | Z-VAD-FMK費用 | Z-VAD-FMK生産者 | オーダーZ-VAD-FMK | Z-VAD-FMK化学構造 | Z-VAD-FMK分子量 | Z-VAD-FMK代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID